AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 212 min read$LABT

Lakewood-Amedex Biotherapeutics Inc. (LABT) Presents Nu-3 Antimicrobial Data at IDWeek

Lakewood-Amedex Biotherapeutics shared preclinical data showing Nu-3's broad-spectrum activity and low resistance. The company is conducting a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. According to the company, the drug demonstrated rapid activity in tests.

Original reporting
tradingview.com
Published Oct 21, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lakewood-Amedex Biotherapeutics Inc. (LABT) Presents Nu-3 Antimicrobial Data at IDWeek — source image
Source · tradingview.com
Decision brief

The 30-second read

$LABTBullishLow
01

Why it matters

The announcement provides the first public data on Nu-3, creating a near‑term catalyst for the stock.

02

Market read

Early‑stage trial data can drive speculative moves in small‑cap biotech stocks.

03

What to watch

Funding requirements for later‑stage trials and competition from larger antimicrobial developers.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Lakewood-Amedex Biotherapeutics (LABT) presented Nu-3 antimicrobial preclinical results at IDWeek and highlighted an ongoing Phase 2a trial in diabetic foot ulcers.

Company-level read

Ticker impact

$LABTBullishHigh confidence
Context

Lakewood-Amedex Biotherapeutics disclosed preclinical data on Nu-3 and a Phase 2a trial with topline results expected Q1 2027.

Expected impact

potential upside as the market prices in successful Phase 2a results

Evidence & confidence

Early‑stage antimicrobial data is a material catalyst for a biotech; the first public disclosure typically drives speculative buying.

Market effects

Sector

Antimicrobial biotech sector may see increased investor interest.

Regional

U.S. biotech investors could allocate more capital to early‑stage infection therapies.

Global

Limited to niche biotech investors; no broad market effect.

Counterpoint

What could challenge this read

The data are preclinical; success is uncertain and could lead to disappointment if Phase 2a fails.

Key entities

  • company
    Lakewood-Amedex Biotherapeutics Inc.

    Biotech developer of the Nu-3 antimicrobial candidate.

Read at source← All news

StoryLakewood‑Amedex presents preclinical data on Nu‑3 antimicrobial at IDWeek 2026

Related articles

OCT 7
$LABTMedAI 8/10

A compound inhibited up to 97% of E. coli growth in rodents; the control group showed no effect.

Lakewood-Amedex Biotherapeutics (LABT) reported preclinical data showing its Bisphosphocin compound Nu-8 inhibited up to 97% of E. coli growth in rodents. Aerosol formulations also showed activity against pulmonary infections. The company plans further development to identify a clinical candidate. Nu-3 is in a Phase 2a trial for diabetic foot ulcers, with topline data expected in Q1 2027.

stocktitan.net2 min
OCT 7
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Lakewood-Amedex Biotherapeutics reported positive preclinical data for its Bisphosphocin® compounds, showing up to 97% inhibition of E. coli growth in urinary tract infections and activity against resistant bacteria in pulmonary infections. The company's lead candidate, Nu-3, is in a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. The Bisphosphocin® class aims to combat antibiotic-resistant strains.

prnewswire.com2 min
SEP 28
$LABTMedAI 8/10

Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections

Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial for Nu-3, a gel treating mildly infected diabetic foot ulcers. The trial will assess safety, efficacy, and optimal dosage. Results are expected in Q1 2027, with potential Phase 2b advancement if successful. According to the company, Nu-3 aims to reduce antimicrobial resistance by targeting infections locally.

proactiveinvestors.com2 min
SEP 24
$LABTLow

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.

prnewswire.com2 min
SEP 21
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and clinical site readiness to start a Phase 2a trial for its lead product, Nu-3, treating infected diabetic foot ulcers. The trial aims to evaluate Nu-3's safety and efficacy, building on positive preclinical data. The company aims to address antibiotic-resistant bacterial strains with its Bisphosphocin® class of antimicrobials.

insidermonkey.com2 min